• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Emergent BioSolutions

    Quotient Sciences

    Adare Pharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Almac Group

    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: CMOs and CDMOs Have a Trade Association to Call Their Own

    The new Pharma & Biopharma Outsourcing Association aims to help advance the industry’s regulatory, legislative and business interests.

    Related CONTENT
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Mogene
    • Metrics Contract Services
    • Halo Pharma Forms Pediatric Center of Excellence
    • So You Think You Know All About Excipients?
    11.13.14
    A new non-profit trade association—The Pharma & Biopharma Outsourcing Association, or PBOA, has been formed to advocate industry causes.

    The association was conceived and launched by former Contract Pharma editor Gil Roth because, he said, “The CMO/CDMO industry has grown tremendously in the past 15 years, but the absence of a group like the PBOA has kept it from reaching its full potential.”

    So far fifteen CMOs/CDMOs have climbed aboard, representing large and small molecule manufacturers, from APIs to finished dosage forms, with members covering the gamut from single-site to globally networked companies.

    In addition to advocating and representing its industry before regulatory, governmental, and legislative bodies, PBOA hopes to educate pharma and biopharma companies, the general public and other stakeholders on the value that CMOs/CDMOs bring to the development and manufacture of therapeutics.

    Contract Pharma talked to Gil about the association’s beginnings and what the plans are moving forward. For more information about the PBOA, visit www.pharma-bio.org, or contact Gil at gil.roth@pharma-bio.org.

    –TW



    Contract Pharma: Tell me about the PBOA. What is it, how will it work and who can benefit from it?
    Gil Roth: The Pharma & Biopharma Outsourcing Association is a non-profit trade association that represents contract manufacturing organizations and contract development and manufacturing organizations (CMO/CDMOs). As we start out, we’re focused on companies that operate in or sell into the U.S. If you’re a CMO or CDMO that interacts with FDA, we want to be your go-to trade group.

    We’ll work to bring our members into the conversation with FDA, Congress, and other trade groups that affect the industry. We’ve partnered with a Washington, DC-area law firm that will provide both regulatory and legislative monitoring and help us reach the offices we need to reach, in order to get our message heard.

    CP: Since the launch how are things going so far? What kind of response/feedback have you had from the industry?
    GR: I’ve been very gratified by the response from industry. I began recruiting member companies in March of this year, and we quickly built a core of 15 members that were enthusiastic about giving this industry a voice. The founding members include Afton Scientific, Coldstream Laboatories, Cook Pharmica, Gallus Biopharmaceuticals, Halo Pharma, Hospira One 2 One, Jubilant HollisterStier, Metrics Contract Services, Patheon, Therapure Biomanufacturing, and WellSpring Pharma Services. We also added “Day One” general members in AAIPharma Services/Cambridge Major Labs, Coating Place, Confab Labs and DPT.

    Those founding members each nominated a member to our board of trustees, and the board has done a great job of getting the PBOA off the ground. As you can see from the list of companies, the PBOA is bigger than any one sector of the CMO/CDMO market, covering dosage form and drug substance, biologics and small molecules, sterile injectables and oral solid dosages, and development through commercial. Our trustees help guide the agenda for the PBOA, while also providing me with management expertise, recruitment heft, and a lot of other capabilities. The board members are willing to be active participants and have helped me reach out to more potential members.

    We’re also in the process of building a strong advisory committee, chaired by PharmSource president Jim Miller and including industry veterans from both the client and provider sides.

    CP: What were the key drivers behind the establishment of the association?
    GR: The idea for a trade association came about when I was reporting on an article for Contract Pharma early in 2013. It was on the topic of the Generic Drug User Fee Amendments (GDUFA), and a number of CMOs I spoke to felt that the allocation of facility fees was unfair. The more I researched and reported, the clearer it became that there was no one advocating for the CMOs’ interests during the GDUFA negotiating sessions, when those fees were being structured.

    I began asking around the industry whether a trade association would be a good idea. Even the companies that weren’t complaining about GDUFA—either because they’re not in the generics space or their companies also have their own generic lines—understood that it’s important that our industry has representation and that we need to have a coordinated message.

    So, the consensus was that a trade association would be a great idea, but no one was in a position to launch and run one.
    Shortly after that, a group of biologics-oriented CMOs approached me at BIO 2013 and wanted to get my thoughts about assembling a trade association for CMO/CDMOs. None of that group had been part of my informal poll, but they’d developed the same idea on their own.

    With their support, I organized a symposium with around 30 CMO/CDMOs, in September 2013, the night before Contract Pharma’s annual conference and exhibition, and received great response and feedback from the assembled group. It seemed like the time was right to build an association to represent this industry in Washington and beyond. It took a few months for me to realize that I wasn’t going to be able to get it rolling while I was still at Contract Pharma.

    CP: What opportunity does this represent for contract manufacturers? How will inclusion help benefit business?
    GR: The PBOA represents the first real opportunity for CMO/CDMOs to have their voices heard as an industry. In addition to our goals of outreach to regulatory and legislative bodies—that is, FDA and Congress—we’re also intent on working with the customer side of the industry. The PBOA can help disseminate best practices and get clients and providers to work together more effectively. More than that, we can get member companies talking to each other, through networking events, workshops and the like.

    The PBOA has three key areas:
    1. Advocacy/Representation with regulatory and government agencies. Our goal is to serve as the guidance organization for regulatory agencies globally when legislation and policy affect the industry. We will work to ensure the development of laws and policies that promote balanced oversight and the advancement of our industry.

    2. Education of members, customers, and general public. We’ll monitor legislation, regulation and media activity that impacts the CDMO industry and provide analyses to members to help them be prepared to address changes. We plan to offer excellent networking, information-sharing and educational resources designed to keep members informed of industry issues. We will educate customers and other stakeholders about the value CDMOs bring to the pharma and biopharma industries.

    3. Collaboration around common industry goals. Our members will help develop our agenda regarding issues that affect our industry and can simplify or promote the efficient growth of our businesses. Some initiatives include common third-party auditors program acceptance, Business Solutions partnerships to provide discounts on goods and services that our members use, and industry research to help get a better picture of the CMO/CDMO industry.

    CP: What are the obstacles to getting off the ground and what do you perceive will be the major challenges to making the association a success?
    GR: I think the biggest obstacle is that no one has ever done this before for our industry. It’s a cliché, but it really is both an obstacle and an opportunity.

    When I began recruiting companies to join the PBOA last spring, one person said to me, “When I joined the industry six years ago, the first thing I asked my company was, ‘What trade associations do we belong to?’ When they told me there aren’t any, I started to worry that I made the wrong career choice.’” That company joined on the spot.

    Still, the CMO/CDMO industry has a lot of players that are so concerned about the day-to-day operation that they don’t have time to step back and take in a broader, longer-term perspective. So it can be a challenge to get them to take that step back, and then to make the investment in time, money and resources that the PBOA requires.

    It’s amazing that we’ve come as far as we have without having any sort of collective body in place to advocate for the industry, but given the pressures that the entire healthcare ecosystem is experiencing, it’s not a state of affairs that can last much longer. I like to cite a quote that’s been attributed to a variety of Louisiana politicians, “If you’re not at the table, then you’re probably on the menu.”

    CP: Describe your interaction with FDA. Have they been receptive to the PBOA?
    GR: Our first meeting with FDA came about somewhat by accident, but we were well received. Along with two members of our Board, I attended a public hearing about several GDUFA guidances in September. We didn’t think the topics would be relevant to the CMO/CDMO side of things, but we wanted to get a feel for this sort of hearing, to see what the presentations were like and how the FDA panel conducted its questioning.

    Lo and behold, the second presentation was from a small generic drug company and was focused completely on GDUFA’s facility fees and how the “no-waiver” policy was unfair to smaller manufacturers. Both trustees nudged me to sign up for the open comments portion at the end of the morning session, where I would get five minutes at the podium in front of the FDA panel. I did, then began scribbling notes about GDUFA, facility fees, the bill that one of our members lobbied his Representative to introduce (H.R. 3631, the Small Manufacturer Protection Act), which would permit FDA to waive those fees for companies under a certain threshold, and more.

    When my turn came up, I took to the podium, adjusted my tie, and introduced the PBOA to the FDA on the public record. My presentation only took up a few minutes, and focused on the need for more interaction between FDA—not just the Office of Generic Drugs—and CMOs/CDMOs. The panel members’ questions were cordial and it really felt like they were welcoming us aboard. They seemed legitimately interested in understanding more about this business and how it differs from in-house pharma and biopharma operations.

    CP: What are the PBOA’s ultimate goals, both short- and long-term?
    GR: In the short term, we want to build bridges to connect the CMO/CDMO industry with FDA and Congress, educate both clients and providers about best outsourcing practices, and bring our industry into the 21st century.

    In the middle term, if we can succeed with our initiative in developing baseline auditing standards between manufacturers and clients, we can not only provide savings for both parties, we may be able to demonstrate to FDA and other regulatory bodies that CMO/CDMOs are committed to quality above and beyond cGMP. Along with our regulatory/legislative advocacy activities, that could go a long way toward changing the image of our industry.

    In the long term, if this model works, we could expand into other areas of outsourcing, as well as other geographic regions. But I spent enough years writing articles about the perils of “scope creep” to know that we need to stick with our initial mission. 
    Related Searches
    • contract manufacturing organizations
    • biopharma companies
    • Dosage
    • contract pharma
    Suggested For You
    5 Reasons Paper Has No Place in Contract Manufacturing 5 Reasons Paper Has No Place in Contract Manufacturing
    Mogene Mogene
    Metrics Contract Services Metrics Contract Services
    Halo Pharma Forms Pediatric Center of Excellence Halo Pharma Forms Pediatric Center of Excellence
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    CROs & Next-Gen  Drug Development CROs & Next-Gen Drug Development
    Aseptic Manufacturing Trends Roundtable Aseptic Manufacturing Trends Roundtable
     Vantage Consulting is First Systems Integrator to Join PBOA Vantage Consulting is First Systems Integrator to Join PBOA
    PBOA Praises Action On FDA Reauthorization  PBOA Praises Action On FDA Reauthorization
    Reality and Un-Reality:  Continuous Processing in Pharmaceutical Manufacturing Reality and Un-Reality: Continuous Processing in Pharmaceutical Manufacturing
    DCAT Week DCAT Week '17 Q&A: API Market Trends
    PBOA President Discusses the Future of the CMO Industry at INTERPHEX PBOA President Discusses the Future of the CMO Industry at INTERPHEX
    Whither Washington? Whither Washington?
    The Good, the Bad, and the Donald The Good, the Bad, and the Donald
    GDUFA II Update GDUFA II Update

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Preparing Your Post Pandemic Talent Strategy

      Preparing Your Post Pandemic Talent Strategy

      Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
      Neil Kelly, Managing Partner, Vector Partners 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21


    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login